PPARA and metabolic dysfunction-associated steatohepatitis: Especially, PPARα agonist has previously been reported to alleviate NASH in many aspects, including preventing lipid accumulation, reducing intrahepatic macrophages and hepatic stellate cell to lower liver inflammation and fibrosis, but clinical trials of pure PPARα agonist are disappointing23.